Atomic bomb survivors/RAS oncogene/PCR/Neutron/Radiation-induced leukemia To determine what the role of RAS oncogene is in radiation-induced leukemia, we investigated the frequency of mutations and the sites of the base substitution of activated N and K-RAS oncogenes in 25 leukemic patients who had been exposed to the atomic bomb and compared the results with those for 47 non-exposed leukemic patients. To detect the presence of mutated RAS oncogene, we used the PCR method to analyze DNAs from leukemic cells and from nude mouse tumors formed by in vivo selection assay.
INTRODUCTION
The use of molecular biology techniques has shown that oncogenes are involved in tumor development. Several transforming oncogenes have been identified in a variety of human cancers by in vitro transfection assays of the mouse NIH3T3 cell line. Activation of the RAS oncogene family (N-, H and K-RAS) is attributed to a single point mutation localized at codons 12, 13 and 61. Experimental evidence from laboratory animals and clinical observations of human cancers suggest that activation of the RAS oncogene is associated with an early as well as late event in carcinogenesis1 '2) . Activation has been found in cells from morphologically normal mammary glands, 12 days after exposure to a carcinogen 3~, and in premalignant cells in the form of adenomas and colon polyps4,5). It also has been found in the metastatic stages of mouse and human tumors6 8 .
Atomic bomb survivors constitute a unique population that has experienced whole body exposure to a large doses of a gamma-ray and neutron mixture. Significantly higher incidences of leukemia and cancer have been reported in atomic bomb survivors, especially heavily exposed individuals, than in the general Japanese population9). The leukemias of the atomic bomb survivors provide a suitable human model with which to study the mechanism(s) that produces radiation-induced leukemia, but the human oncogene(s) associated with the development of leukemia or carcinoma induced by radiation has not been well studied. At present, alteration of proto-oncogenes, particularly the RAS oncogene, appears to be a main component of the leukemogenesis process in radiation-induced leukemia. We investigated the frequency of RAS mutations and the sites of base substitution in 25 leukemic patients exposed to the atomic bomb blast and compared the results with those for 47 non-exposed leukemic patient.
PATIENTS AND METHODS

Patients
Twenty-five leukemic patients who had been exposed to the Hiroshima atomic bomb blast have been given annual cytogenetic examinations for the last 10 years. The development leukemia in these patients took place 35 to 45 years after the bombing. All had been exposed to the bomb's radiation within 2.7 km of the blast hypocenter, 5 within 1 km, 19 within 1-2 km and one at 2.7 km. The estimated exposure doses ranged from 0.01 to 8.47 Gy on the basis of the T65D and DS86 dosimetries10). Of these leukemic patients 8 had chronic myelocytic leukemia (CML), 4 had acute lymphocytic leukemia (ALL) and 13 had acute non-lymphocytic leukemia (ANLL). In the ANLL series, 6 patients were classified M1, two M2, one M4 and 4 refractory anemia with excess blasts (RAEB) as per the French-American-British (FAB) categorization . For the comparative study, 47 non-exposed leukemic patients; 25 with CML, 14 with ANLL (AML M1: 4, M2: 4, M3: 3, M4: 2 and RAEB: 1) and 8 with ALL were used as subjects.
Cytogenetic analysis
Bone marrow cells from all 72 leukemic patients were cultured for 24 h. and then subjected to G-banding for chromosome analysis. The karyotype was described according to the ISCN (1985)11
DNA analysis
DNAs from the leukemic cells and from nude mouse tumors formed by in vivo selection assay were analyzed by the polymerase chain reaction (PCR) method to determine whether activated RAS oncogenes were present. find the sites of the point mutations on the N-RAS and K-RAS oncogenes12-14). A 0.5-1 ,u g DNA samples was amplified with the 3' and 5' primers for N-RAS codons at the 12th, 13th and 61st positions, and for the c-K-RAS codons at the 12th and 61st positions ( Table 1 ). The DNA samples were amplified with PCR in a DNA thermal cycler (Perkin-Elmer/Cetus). Each 30 1 reaction tube contained 0.5-1,ug DNA, lOx reaction buffer (500mM KCI, 100mM Tris-HC1 pH 8.3, l5mM MgCl2, 0-1% gelatine), 2.5 mM dNTP's, 100pmol 5' primer and 3' primer, 2.Op 1 Taq polymerase (TAKARA). The reaction mixtures were heated for seven minutes at 94°C then cooled to 65°C for 6 minutes. This cycle . was repeated 40 times after initial conditioning of 1.5 minutes at 94°C for denaturing, 1.5 minutes at 51°C for annealing and 3 minutes at 65°C for primer extension. Bone marrow DNA and lymphocyte DNA from healthy persons were the negative controls. DNAs from HL-60 and MOLT4 cell lines were the positive controls used to detect the point mutations of the N-RAS 61 and K-RAS 12 codons (N61 and K12). Two microliter samples of the reaction products were transferred to nylon filters by dot blotting (Bio-Rad microfilteration). Each filter was hybridized with 19 mer mutant-specific nucleotide probes with one base substitution in the N-RAS and K-RAS genes. The probes used are shown in Table 1 . The probes for detecting the nucleotide substitution at letters 1, 2 and 3 were in a mixed condition for the screening. They were labelled by the 5' end labelling method with p32 r -ATP and polynucleotide kinase. Hybridization was done at 55-65'C in 5 x SSC + 0.107o SDS solution. The filter was washed with 0.5xSSC + 0.1070 SDS and 0.1 x SSC +0.1% SDS for 30 minutes each at room temperature. The final wash was with 0.1 xSSC+0.1010 SDS and 3M tetramethyl ammonium chloride (TMAC) at a temperature (Tm-1 °C) that depended on the base composition of the probe.
Analyses of DNAs extracted from nude mouse tumors
Bone marrow cells of 45 patients (17 exposed and 28 non-exposed) out of 72 cases were given in vivo selection assays according to the methods described by Bos JL et a1.15) and Hirai H16> A total 40-80,a g donor DNA was co-transfected with 2 ,u g of plasmid pSV2Neo DNA to NIH3T3 cells by the calcium-phosphate method. The transfected cells were selected in medium with the antibiotic G418 (400p g/ml). Cells that showed growth after one week were collected by trypsinization. Injections of 1.5 x 106 cells were made at two subcutaneous sites in each nude mouse. Two to three mice were used per patient for this analysis. Tumors appeared 4-8 weeks after the inoculation of the transfected cells. DNAs from bone marrow cells of three healthy donors and from placenta were used as the controls. Nude mouse tumor DNAs were extracted and used for Southern blotting in order to determine the human-specific Alu sequence. BLUR8 probe (BamHI 0.3kb fragment) (Japanese Cancer Research Bank: JCRB) 17) was used for this analysis. The transforming RAS gene family (N-RAS, c-K-RAS and c-H-RAS) in each patient was detected with the representative probes N-RAS (Pvull 2.0kb) (courtesy of Dr. A. Hasegawa, Tonen Corporation), c-K-RAS (EcoRl=Hind III 2.0kb) (Oncogene Science Inc.)18) and c-H-RAS (Sac! 2.9kb) (JCRB)19). Tumor DNAs used for in vivo selection assay also were analyzed by the method described to locate the sites of the point mutation of the N-RAS and K-RAS oncogenes. 
RESULTS
The number of patients with mutations of the RAS oncogene and the sites of the base substitution in the leukemic cells analyzed by PCR are shown in Table 2 . No significant differences between the exposed and non-exposed groups were found in the frequency of RAS oncogene mutation in any of the leukemic types nor in the sites of the base substitution.
Detection of transforming genes in the tumor DNA of radiation-exposed leukemic patients by use of the in vivo selection assay showed five were positive for N-RAS and one positive for K-RAS (Figure 1 ). The N-RAS positive patients had one CML, two ANLL, one ALL and one RAEB. The K-RAS positive patient had a CML. The frequencies of Alu-positive tumors, the types of transforming genes, and the sites of the base substitution are tabulated in Table 3 for both leukemic groups. No marked difference was found between the exposed and non-exposed groups in the frequencies of Alu-positive tumors, the types of transforming genes, and the sites of the base substitution. Tumor formation did not take place in nude mice injected with the DNAs of cells from NIH3T3, placenta and two of the three healthy persons. The DNA from one healthy person developed tumors at two sites in a nude mouse 60 days after its inoculation with transfected NIH3T3 cell DNA. The latent period for tumor development was much longer than for the leukemic patient DNA. One tumor contained the human-specific Alu sequence but there was no mutation of the RAS oncogene. PCR analysis of the DNAs from the leukemic and nude mouse tumor cells showed alterations in the base constitution of the RAS oncogene in eight of the 25 atomic bomb-radiation exposed leukemic patients (32%) and 13 of 47 non-exposed leukemic patients (27.6%). Molecular and cytogenetic findings for the eight patients with base substitutions are given in Table 4 . Changes in the bases of N-RAS codon 12 letter 1 (N 12P 1) of patient 1, the N 16P 1 of patient 2, the K 12P 1 of patient 3 and the N 12P2 of patient 7 were not determined as only a small amount of DNA was available. The oligonucleotide hybridizations of N61 P2 and K61 P2 are shown in Figure 2 . Three of the 8 exposed patients (37.5%) had base substitution at more than two sites on the RAS oncogene (Table 4) , and 3 of the 13 patients (23%) in the non-exposed group had mutations at multiple sites. These percentages were not statistically significant (Chit= 0.0027, p=0.96, after Yate's correction). Tumor DNAs from the in vivo selection assays of two of the radiation-exposed leukemic patients were used for DNA sequence analysis. One of the two patients showed an abnormality at codon 31 of the N-RAS oncogene (GAA to GAT; glutamine to aspartic acid). Chromosome analyses of members of the exposed group revealed abnormalities in seven, of which six had multiple aberrations that involved more than five chromosomes (Table 4) .
DISCUSSION
Mutation of the RAS oncogene has been found even during the initiation stage of carcinogenesis in mice treated with DMBA or MNU20). These carcinogens are suggested to be directly induced base substitutions on the RAS oncogene21). Kumar Fig. 2 . Dot blot differential hybridization analysis for mutation of N-RAS codon 61 letter 2 (N61 P2) and K-RAS codon 61 letter 2 (K61 P2) in atomic bomb exposed leukemic patients and non-exposed leukemic patients. DNA (0.5-1,u g) from tumor samples of the in vivo selection assay and the patient's original DNA were amplified by PCR. The products were spotted on filters and hybridized with wild (NW, KW) and mutant specific oligonucleotides probes of N-RAS or K-RAS codon 61 . Samples with an asterisk (*) are from atomic bomb-exposed leukemic patients . Samples with small or no spots in the hybridization with normal NW and KW probes (shown at far left) were not amplified because human RAS genes were not integrated in the tumor DNAs by the in vivo selection assay .
Our study shows that eight of the 25 atomic bomb-exposed leukemic patients had mutations Table   4 . Point mutation of RAS oncogenes in atomic bomb-exposed leukemic patients IV: in vivo selection assay, S: DNA sequencing, NS: not estimated * T65D , ** estimated from the lymphocyte chromosome aberration frequency at codons 12, 13 and 61 of the N-RAS or K-RAS oncogene. The frequencies of RAS oncogene mutations did not differ for the radiation-exposed and non-exposed leukemic groups. The radiation-exposed leukemic patients did not show mutation at a specific RAS oncogene site.
Mutations of the RAS oncogene have been found in less than 10% of CML and in 30-40%
of AML and ALL patients [22] [23] . These frequencies correspond well with our results for the radiation-exposed and non-exposed leukemic patients. We found transition in base substitutions in 8 of the radiation-exposed leukemic patients that was similar to that in de novo leukemic patients as reported by Bos JL25). As shown elsewhere, the second letter in each codon is commonly associated with substitution 25). This was true in our series for 6 of the 8 patients in the radiation exposed group. These results indicate that activation of the N-RAS or K-RAS oncogene is closely associated with leukemogenesis, irrespective of exposure to radiation. Activated RAS oncogenes have been found in leukemias and lymphomas induced by radiation in the experimental animals [26] [27] [28] . Gamma-ray-induced mouse thymic lymphomas have mutations at codon 12 of the N and K-RAS oncogenes29); gamma-ray or neutron-induced lymphomas in the mouse also show abnormalities at K12 and N61 of the RAS oncogene; and gamma-ray-induced canine AML mutation at codon 12 of N-RAS301 The incidence of mutation in the RAS oncogene was not significantly high in any leukemic type from the radiation-exposed leukemic group. The reason is unclear, but one possibility is that the atomic bomb-related leukemias seen 35-45 years after the explosion may have co-existed with de novo leukemia events. Our previous cytogenetic study done on a heavily radiation-exposed group (more than one Gy) of acute leukemic patients showed a higher incidence of chromosome abnormality and a higher degree of complex chromosome aberration than for the non-exposed group, the frequencies being 100% in the exposed and 61.9% in the non-exposed group31). In the study reported here, we found the respective frequencies of chromosome aberration in the exposed and non-exposed acute leukemia patients to be 81.3% (13 of 16 analyzable patients) and 54.5% (12 of 22 analyzable patients) (data not shown). This suggests that the radiation-exposed group of this study is a good model for radiation-induced leukemia because of the high frequency of chromosome aberration in the atomic bomb-exposed group. The possibility that the co-existence of de novo leukemia events in the exposed group might be less also is suggested. Yet another possibility is that there may have been a higher frequency of RAS mutation in the short latent period than long latent period (35-45 years) leukemias in the radiation-exposed group; therefore, the frequency of RAS mutation in long latent period leukemia was the same as in de novo leukemia (non-exposed). To verify the specific role of RAS mutation in leukemogenesis, it is necessary that molecular biological studies be made with the PCR method using paraffin block samples from patients who developed leukemia at an early time after atomic bomb exposure.
Neutron-induced mutations are reported to be in several codons other than 12, 13 and 61; those commonly associated with leukemogenesis caused by carcinogens such as gamma-rays29). Tumor DNAs from the in vivo selection assay of two atomic bomb-exposed leukemic patients were analyzed for the DNA sequence of the N-RAS gene. One patient's DNA (patient 5 in Table  4 ) showed mutation at codon 31 of the gene, which has not been reported previously. This mutation may be associated with activation of the N-RAS gene in leukemogenesis. Detailed analyses of the entire RAS gene sequence now is needed in a large number of radiation-induced leukemic patients.
Atomic bomb-exposed leukemic patients who showed transforming activity but no mutation in their N-, K and H-RAS genes must have had other transforming genes such as RAF, REL, MET, NEU and, possibly, unidentified oncogenes. Following exposure, clonal expansion of cells with mutated codons would have occured, eventually leading to a sufficiently large abnormal cell population to allow detection of abnormal protein. Factors other than the activation of RAS oncogene (such as activation of other oncogenes32), loss of anti-oncogene, alteration of the immune/endocrine systems, or activation of growth factors) also may be associated with the genesis of radiation-induced leukemias.
